Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Core Viewpoint - Allarity Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, which is a positive development for the company as it continues to focus on the clinical potential of its lead asset, stenoparib, for advanced ovarian cancer treatment [1][2]. Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian cancer patients [3]. - The company utilizes its DRP® companion diagnostic for patient selection in its ongoing phase 2 clinical trial, NCT03878849 [3]. Compliance Achievement - On April 27, 2024, Allarity received formal notice from Nasdaq confirming that its stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days since April 9, 2024, thus meeting the requirements for regaining compliance with Nasdaq's Listing Rule 5550(a)(2) [1]. CEO's Statement - The CEO of Allarity expressed optimism regarding the clinical potential of stenoparib based on promising early data from the ongoing phase 2 trial and emphasized the company's commitment to addressing the urgent needs of advanced ovarian cancer patients [2].